FDA: Benefits still outweigh risks from paclitaxel-coated devices for PAD

Friday, January 25, 2019

This week, the FDA weighs in on concerning reports about paclitaxel-coated stents, and it approves a device to treat patent ductus arteriosus in infants weighing as little as 2 pounds. Also, a treat-to-target approach for CVD risk factors decreased atherosclerosis in rheumatoid arthritis patients, and ezetimibe was effective for primary prevention in elderly patients.

How to Listen

Podcast Participants

^{Jim Dwyer, MD}

Jim Dwyer MD, FACC, FSCAI, is a cardiologist and avid horseman in Prescott, Ariz. Trained at Saint Louis University, he spent more than 30 years in interventional cardiology. He recently hung up his lead apron and has joined a private cardiology practice. Dr. Dwyer has been producing health segments for radio broadcast for 20 years. He has no disclosures.